Julie leads investments and company formation efforts in biopharma that tangibly improve patient care. Since joining Canaan in 2013, Julie has incubated, financed and supported investments in multiple new biopharmaceutical companies including Day One Biopharmaceuticals (DAWN), Reactive Biosciences, Nocion, Synthekine, Protagonist (PTGX), Cellular Research (Acquired by Becton Dickinson), Dermira (DERM), Labrys Biologics, CytomX (CTMX), and Unchained Labs.
Prior to joining Canaan, Julie worked at Genentech bringing new oncology products to market in roles spanning business development, cross functional management and commercial. Julie serves on The National Cancer Advisory Board, appointed by President Biden in 2023. She holds an M.B.A. from Stanford’s Graduate School of Business, a M.Phil. from Cambridge University in BioScience Enterprise and a B.S. in Molecular Biophysics and Biochemistry from Yale University.
Julie in 5
Origins: Grew up next to The Second City in Chicago
Interests: Maintaining a strict diet of daily dark chocolate consumption
Travel: Weekend skiing & hiking retreats in the Western mountain ranges
Accomplishments: College sailing national champion